7 min. read

Digital health formulary wars heat up. $40M price tag for a digital drug.

Issue 007. Digital health formulary wars heat up. $40M price tag for a digital drug.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a likely-not-to-be-repeated 89 percent open rate. Here's what's happening this week:

  • Your editor is preparing to take his 3-year-old and 5-year-old camping for the first time this weekend. Hit reply to talk me out of it (or to send more marshmallows).
  • Dexcom CEO Kevin Sayer told Jim Cramer in the next 12 months the company will launch the G6 version of its CGM that sends data direct-to-Apple Watch (bypassing the iPhone).
  • Benjamin D'hont of Alcimed has a helpful overview of the current state of digital therapeutics here.
  • Elsewhere, I've heard some curmudgeons throwing cold water on digital health companies that call themselves "digital therapeutics" if they use either CBT or real live

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Recent Articles